These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 6839551)

  • 1. Antipyrine metabolism in patients with diabetes mellitus.
    Murali KV; Adithan C; Shashindran CH; Gambhir SS; Chandrasekar S
    Clin Exp Pharmacol Physiol; 1983; 10(1):7-13. PubMed ID: 6839551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salivary antipyrine kinetics in hepatic and renal disease and in patients on anticonvulsant therapy.
    Harman AW; Penhall RK; Priestly BG; Frewin DB; Phillips PJ; Clarkson AR
    Aust N Z J Med; 1977 Aug; 7(4):385-90. PubMed ID: 270989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saliva and plasma clearance of antipyrine as reflectors of liver function.
    Luoma PV; Sotaniemi EA
    Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study of antipyrine pharmacokinetics in saliva and plasma using a colourimetric method of antipyrine analysis.
    Harman AE; Priestly BG; Frewin DB
    Clin Exp Pharmacol Physiol; 1977; 4(6):593-6. PubMed ID: 589875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of salivary concentration data to pharmacokinetic studies with antipyrine.
    Meffin PJ; Williams RL; Blaschke TF; Rowland M
    J Pharm Sci; 1977 Jan; 66(1):135-7. PubMed ID: 833730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of antipyrine kinetics by measurement in saliva.
    Fraser HS; Mucklow JC; Murray S; Davies DS
    Br J Clin Pharmacol; 1976 Apr; 3(2):321-5. PubMed ID: 973966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elimination of antipyrine from saliva as a measure of metabolism in man.
    Welch RM; DeAngelis RL; Wingfield M; Farmer TW
    Clin Pharmacol Ther; 1975 Sep; 18(3):249-58. PubMed ID: 1164815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of etiocholanolone-induced fever on plasma antipyrine half-lives and metabolic clearance.
    Elin RJ; Vesell ES; Wolff SM
    Clin Pharmacol Ther; 1975 Apr; 17(4):447-57. PubMed ID: 1122686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of diabetes mellitus on drug metabolism in man.
    Daintith H; Stevenson IH; O'Malley K
    Int J Clin Pharmacol Biopharm; 1976 Jan; 13(1):55-8. PubMed ID: 1248919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics of antipyrine in patients with graded severity of schistosomiasis.
    el-Raghy I; Back DJ; Osman F; Nafeh MA; Orme ML
    Br J Clin Pharmacol; 1985 Oct; 20(4):313-6. PubMed ID: 4074599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.
    Danhof M; van Zuilen A; Boeijinga JK; Breimer DD
    Eur J Clin Pharmacol; 1982; 21(5):433-41. PubMed ID: 7075648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers.
    Bartoli A; Gatti G; Cipolla G; Barzaghi N; Veliz G; Fattore C; Mumford J; Perucca E
    Epilepsia; 1997 Jun; 38(6):702-7. PubMed ID: 9186253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salivary antipyrine half-life during injectable progestagen contraception.
    Joshi JV; Gupta KC; Hazari KT; Gokral J; Pohujani S; Satoskar R
    Clin Pharmacokinet; 1986; 11(2):171-5. PubMed ID: 3956050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impairment of human antipyrine metabolism by piroxicam.
    Battellino LJ; Dorronsoro de Cattoni ST; Ragagnin C
    Can J Physiol Pharmacol; 1990 Jun; 68(6):711-7. PubMed ID: 2372742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipyrine metabolism during the menstrual cycle.
    Riester EF; Pantuck EJ; Pantuck CB; Passananti GT; Vesell ES; Conney AH
    Clin Pharmacol Ther; 1980 Sep; 28(3):384-91. PubMed ID: 7408398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of chloroquine and primaquine on antipyrine metabolism.
    Back DJ; Purba HS; Park BK; Ward SA; Orme ML
    Br J Clin Pharmacol; 1983 Nov; 16(5):497-502. PubMed ID: 6639836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine.
    Shaw PN; Houston JB; Rowland M; Hopkins K; Thiercelin JF; Morselli PL
    Br J Clin Pharmacol; 1985 Dec; 20(6):611-8. PubMed ID: 4091993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on theophylline metabolism: autoinduction and inhibition by antipyrine.
    Denlinger CL; Stryker KK; Slusher LB; Vesell ES
    Clin Pharmacol Ther; 1987 May; 41(5):522-30. PubMed ID: 3568537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impairment of antipyrine clearance in humans by propranolol.
    Greenblatt DJ; Franke K; Huffman DH
    Circulation; 1978 Jun; 57(6):1161-64. PubMed ID: 639239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of fever on antipyrine metabolism in children.
    Forsyth JS; Moreland TA; Rylance GW
    Br J Clin Pharmacol; 1982 Jun; 13(6):811-5. PubMed ID: 7093111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.